c-Met Inhibitor DO-2

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, brain-penetrant inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor DO-2 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. The hydrogen-carbon bond(s) has been replaced with deuterium-carbon bond(s) in DO-2 to decrease both the metabolic breakdown of the agent and the resulting levels of inactive and toxic metabolites.

**Synonyms:** - DO 2 - DO-2 - DO2 - MET Kinase Inhibitor DO-2